<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1016/j.isci.2024.110839</dc:identifier><dc:language>eng</dc:language><dc:creator>Oliván-Blázquez, Bárbara</dc:creator><dc:creator>Bona-Otal, Marta</dc:creator><dc:creator>Méndez-López, Fátima</dc:creator><dc:creator>Lerma-Irureta, David</dc:creator><dc:creator>García-Izuel, Paula</dc:creator><dc:creator>Ibáñez-Ruiz, Jesús</dc:creator><dc:creator>Montolío, Alberto</dc:creator><dc:creator>Ruiz-Herreros, María</dc:creator><dc:creator>Godino, Javier</dc:creator><dc:creator>Jimeno-Beltran, Beatriz</dc:creator><dc:creator>Encabo-Berzosa, María del Mar</dc:creator><dc:creator>Arenaz, Izaskun</dc:creator><dc:creator>Medel-Martínez, Ana</dc:creator><dc:creator>Casado-Vicente, Verónica</dc:creator><dc:creator>Coiras, Mayte</dc:creator><dc:creator>Tellería-Orriols, Carlos</dc:creator><dc:creator>Schoorlemmer, Jon</dc:creator><dc:creator>Magallón-Botaya, Rosa</dc:creator><dc:title>Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers</dc:title><dc:identifier>ART-2024-140025</dc:identifier><dc:description>Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12–24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16brightCD56− cell presence distinguished PCC individuals from recovered patients with &gt;88% accuracy and &lt;92% precision.</dc:description><dc:date>2024</dc:date><dc:source>http://zaguan.unizar.es/record/145252</dc:source><dc:doi>10.1016/j.isci.2024.110839</dc:doi><dc:identifier>http://zaguan.unizar.es/record/145252</dc:identifier><dc:identifier>oai:zaguan.unizar.es:145252</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/DGA/B21-23R-GAIAP</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/DGA/B46-20R</dc:relation><dc:relation>info:eu-repo/grantAgreement/EC/H2020/101057302 /EU/SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients/HERVCOV</dc:relation><dc:relation>This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 101057302 -HERVCOV</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/IACS/PT20-00112</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-02208</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/PI22-01070</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII-RICAPPS/RD21-0016-0005</dc:relation><dc:identifier.citation>ISCIENCE 27, 9 (2024), 110839 [16 pp.]</dc:identifier.citation><dc:rights>by-nc</dc:rights><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/deed.es</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>